Comparison of effectiveness of benzhexol and procyclidine in improving tremor in tremor predominant Parkinson's disease patients
NCT ID NCT07810296
First seen Sep 09, 2026 · Last updated Sep 09, 2026
Summary
The goal of this clinical trial is to compare benzhexol and procyclidine for improving tremor in adults with tremor-predominant Parkinson's disease who are taking levodopa. Researchers will compare the two medicines to determine whether benzhexol provides similar improvement in tremor to procyclidine and to assess their side effects. Participants will be randomly assigned to receive either benzhexol or procyclidine in addition to their usual levodopa treatment. Motor symptoms and side effects will be assessed before treatment and at 2 weeks, 3 months, and 6 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 88 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosed Parkinson's disease according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease, with predominant tremor at presentation. * Hoehn and Yahr stage 1, 2, or 3. * Any gender. * Age 40 to 70 years. * Receiving levodopa/carbidopa monotherapy for Parkinson's disease, with resting tremor present. Exclusion Criteria: * Cognitive or behavioral abnormalities. * Lower urinary tract symptoms. * Benign prostatic hyperplasia. * Angle-closure glaucoma. * Cardiac disease.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Parkinson disease (PD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Mayo Hospital Lahore
RECRUITINGLahore, Punjab Province, 54000, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which DBS setting works best for Parkinson's? a trial puts anodic vs cathodic to the test
- Can an inhaled levodopa ease Parkinson's OFF episodes? a study asks patients.
- Can hope and trust boost engagement with rehab robots?
- A simple swallow exercise might ease a hidden Parkinson's danger
- Parkinson's pain: could a new Add-On drug bring relief?
- Can virtual games retrain the brain to restore balance?